Denosumab (Xgeva®)
Cost-effectiveness of denosumab (Xgeva®) for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland.
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 15/08/2011 | 08/12/2011 | Reimbursement Recommended |
We consider denosumab (Xgeva®) a cost-effective therapy for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the Irish healthcare setting.